AIMC Topic: Adenocarcinoma of Lung

Clear Filters Showing 1 to 10 of 179 articles

Unveiling diagnostic biomarkers and therapeutic targets in lung adenocarcinoma using bioinformatics and experimental validation.

Scientific reports
Lung adenocarcinoma (LUAD) is a major challenge in oncology due to its complex molecular structure and generally poor prognosis. The aim of this study was to find diagnostic markers and therapeutic targets for LUAD by integrating differential gene ex...

Prognostic model of lung adenocarcinoma from the perspective of cancer-associated fibroblasts using single-cell and bulk RNA-sequencing.

Scientific reports
Cancer-associated fibroblasts (CAFs) play important roles in the progression of lung adenocarcinoma (LUAD). We examined CAF subgroups via gene ontology, pseudo-time, and cell communication analyses and explored their prognostic value in LUAD using a ...

Fast and accurate lung cancer subtype classication and localization based on Intraoperative frozen sections of lung adenocarcinoma.

Biomedical physics & engineering express
Current lung cancer diagnostic techniques primarily focus on tissue subtype classification, yet remain inadequate in distinguishing pathological progression subtypes (particularly between adenocarcinomaand invasive adenocarcinoma) on frozen sections....

Predicting Gene Comutation of EGFR and TP53 by Radiomics and Deep Learning in Patients With Lung Adenocarcinomas.

Journal of thoracic imaging
PURPOSE: This study was designed to construct progressive binary classification models based on radiomics and deep learning to predict the presence of epidermal growth factor receptor ( EGFR ) and TP53 mutations and to assess the models' capacities t...

Deep learning radiopathomics predicts targeted therapy sensitivity in EGFR-mutant lung adenocarcinoma.

Journal of translational medicine
BACKGROUND: Ttyrosine kinase inhibitors (TKIs) represent the standard first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, not all patients with EGFR mutations respond to TKIs. This study...

F-FDG PET/CT-based deep learning models and a clinical-metabolic nomogram for predicting high-grade patterns in lung adenocarcinoma.

BMC medical imaging
BACKGROUND: To develop and validate deep learning (DL) and traditional clinical-metabolic (CM) models based on 18 F-FDG PET/CT images for noninvasively predicting high-grade patterns (HGPs) of invasive lung adenocarcinoma (LUAD).

The role and machine learning analysis of mitochondrial autophagy-related gene expression in lung adenocarcinoma.

Frontiers in immunology
OBJECTIVE: Lung adenocarcinoma (LUAD) continues to be a primary cause of cancer-related mortality globally, highlighting the urgent need for novel insights finto its molecular mechanisms. This study aims to investigate the relationship between gene e...

MLG2Net: Molecular Global Graph Network for Drug Response Prediction in Lung Cancer Cell Lines.

Journal of medical systems
Drug response prediction (DRP) is a central task in the era of precision medicine. Over the past decade, the emergence of deep learning (DL) has greatly contributed to addressing DRP challenges. Notably, the prediction of DRP for cancer cell lines be...

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with Zr/I-Labeled Tinurilimab.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Lung adenocarcinoma (LUAD) constitutes a major cause of cancer-related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application o...

Development and validation of machine learning models for early diagnosis and prognosis of lung adenocarcinoma using miRNA expression profiles.

Cancer biomarkers : section A of Disease markers
ObjectiveStudy aims to develop diagnostic and prognostic models for lung adenocarcinoma (LUAD) using Machine learning(ML)algorithms, aiming to enhance clinical decision-making accuracy.MethodsData from The Cancer Genome Atlas (TCGA) for LUAD patients...